| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | APLT | Common Stock | Options Exercise | $21.6K | +15K | $1.44 | 15K | Aug 9, 2021 | Direct | F1 | |
| transaction | APLT | Common Stock | Sale | -$177K | -10.3K | -68.67% | $17.18* | 4.7K | Aug 9, 2021 | Direct | F2, F3 |
| transaction | APLT | Common Stock | Sale | -$83.9K | -4.7K | -100% | $17.85* | 0 | Aug 9, 2021 | Direct | F2, F4 |
| transaction | APLT | Common Stock | Options Exercise | -$12.8K | -8.87K | -50% | $1.44 | 8.87K | Aug 10, 2021 | Direct | F1 |
| transaction | APLT | Common Stock | Sale | $131K | +8.27K | $15.85* | 600 | Aug 10, 2021 | Direct | F2, F5 | |
| transaction | APLT | Common Stock | Sale | -$13.1K | -800 | -100% | $16.35* | 0 | Aug 10, 2021 | Direct | F2, F6 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | APLT | Stock Option (Right to Buy) | Options Exercise | $0 | -15K | -12.63% | $0.00 | 104K | Aug 9, 2021 | Common Stock | 15K | $1.44 | Direct | F1, F7 |
| transaction | APLT | Stock Option (Right to Buy) | Options Exercise | $0 | -8.87K | -8.55% | $0.00 | 94.9K | Aug 10, 2021 | Common Stock | 8.87K | $1.44 | Direct | F1, F7 |
| Id | Content |
|---|---|
| F1 | Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised automatically pursuant to the reporting person's written trading plan previously entered into on September 16, 2020, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| F2 | Automatic sales made pursuant to the reporting person's pre-existing written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| F3 | Weighted average price. These shares were sold in multiple transactions at prices ranging from $16.7500 to $17.7400 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| F4 | Weighted average price. These shares were sold in multiple transactions at prices ranging from $17.7500 to $18.0500 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| F5 | Weighted average price. These shares were sold in multiple transactions at prices ranging from $15.2200 to $16.1700 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| F6 | Weighted average price. These shares were sold in multiple transactions at prices ranging from $16.2500 to $16.6100 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| F7 | Thirty-three percent (33%) of the shares subject to the option vested on August 27, 2018, and one twenty-fourth (1/24th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. |